Navigation Links
Cell Genesys to Webcast Third Quarter 2007 Conference Call
Date:10/25/2007

SOUTH SAN FRANCISCO, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE), today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer, and Sharon E. Tetlow, senior vice president and chief financial officer of Cell Genesys, will host a conference call relating to the company's third quarter financial results that will be broadcast live over the internet on Thursday, November 1, 2007, at 2:00 p.m. PT/ 5:00 p.m. ET.

The webcast will be available on the investor relations section of the company's website, http://www.cellgenesys.com. If you are unable to listen to the live webcast, the call will be archived on the website for at least 72 hours following the call. To access the replay, go to the Investor Relations section of the website.

Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at http://www.cellgenesys.com.

Statements made herein about the company, other than statements of historical fact, including statements about the company's, progress, results and timing of clinical trials and preclinical programs and the nature of product pipelines are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials and research and development programs, the regulatory approval process for clinical trials, competitive technologies and products, patents, continuation of corporate partnerships and the need for additional financings. For information about these and other risks which may affect Cell Genesys, please see the company's Annual Report on Form 10-K for the year ended December 31, 2006 filed on August 7, 2007 as well as Cell Genesys' reports on Form 10-Q and 8-K and other reports filed from time to time with the Securities and Exchange Commission. The company assumes no obligation to update the forward-looking information in this press release.

Contact:

Susan Ferris

Investor Relations

650-266-3200


'/>"/>
SOURCE Cell Genesys, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sonic Foundry to Webcast Bridge Arch Floating Down Mississippi
2. Visions: Broderick says Wisconsin should be in top third in venture capital
3. Third Wave files countersuit vs. Digene in patent case
4. Third Wave reports net loss of $18.9M for 2006
5. Stratagene to pay Third Wave $10.75M in patent case
6. Third Wave responds to Digene patent lawsuit
7. Third Wave seeks approval of Cystic Fibrosis test
8. Third Wave Technologies to raise $14.9M through private debt
9. Venture capital above $6B for third straight quarter
10. Third Wave reports $5.2M third quarter loss
11. Third Wave reports another loss, stronger sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back ... 8th June 2018 in San Francisco, CA. The Summit brings together current and former ... CEOs, board directors and government officials from around the world to address key issues ...
(Date:10/11/2017)... 2017  VMS BioMarketing, a leading provider of patient support ... Nurse Educator (CNE) network, which will launch this week. The ... health care professionals to enhance the patient care experience by ... other health care professionals to help women who have been ... ...
(Date:10/11/2017)... ... , ... Disappearing forests and increased emissions are the main causes of the ... Especially those living in larger cities are affected by air pollution related diseases. , ... pollution-affected countries globally - decided to take action. , “I knew I had to ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh ... orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of ... SBT-100 is able to cross the cell membrane and bind intracellular STAT3 and ...
Breaking Biology Technology:
(Date:4/11/2017)... No two people are believed to ... York University Tandon School of Engineering and Michigan ... partial similarities between prints are common enough that ... and other electronic devices can be more vulnerable ... in the fact that fingerprint-based authentication systems feature ...
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
Breaking Biology News(10 mins):